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Cyclooxygenase-2 expression is associated with the renal mac- hyperaldosteronism with hypokalemia and metabolic al-
ula densa of patients with Bartter-like syndrome. kalosis but normal blood pressure [1, 2]. Mutations in at
Background. Bartter-like syndrome (BLS) is a heterogeneous least three genes essential for chloride reabsorption in theset of congenital tubular disorders that is associated with sig-
thick ascending limb of Henle [3–5] and distal convolutednificant renal salt and water loss. The syndrome is also marked
tubule [6] are associated with phenotypically distinct tu-by increased urinary prostaglandin E2 (PGE2) excretion. In
rodents, salt and volume depletion are associated with in- bulopathies [1, 7]. Patients with classic Bartter’s syn-
creased renal macula densa cyclooxygenase-2 (COX-2) expres- drome are characterized by mutations encoding the baso-
sion. The expression of COX-2 in human macula densa has
lateral chloride channel. In contrast, hyperprostaglandinnot been demonstrated. The present studies examined whether
E2 syndrome or antenatal Bartter’s syndrome (HPS/aBS)COX-2 can be detected in macula densa from children with
salt-wasting BLS versus control tissues. is caused by mutations in genes encoding the apical furo-
Methods. The intrarenal distribution of COX-2 protein and semide-sensitive Na-K-2Cl cotransporter and the inwardly
mRNA was analyzed by immunohistochemistry and in situ rectifying renal potassium channel (RomK). The meta-
hybridization in 12 patients with clinically and/or genetically
bolic disturbances in these patients may be amelioratedconfirmed BLS. Renal tissue rejected for transplantation, from
by administration of cyclooxygenase (COX)–inhibitingsix adult patients not affected by BLS, was also examined.
Results. The expression of COX-2 immunoreactive protein nonsteroidal anti-inflammatory drugs (NSAIDs) [1].
was observed in cells of the macula densa in 8 out 11 patients Cyclooxygenase-mediated prostaglandin formation
with BLS. In situ hybridization confirmed the expression of yields a family of labile, bioactive lipids that modulateCOX-2 mRNA in the macula densa in 6 out of 10 cases. COX-2
a variety of physiological and pathophysiological proc-protein was also detected in the macula densa in a patient with
esses, including renal glomerular filtration, renin release,congestive heart failure. The expression of COX-2 immunore-
active protein was not observed in cells associated with the and epithelial salt and water transport [8]. NSAIDs such
macula densa in kidneys from patients without disorders associ- as indomethacin block the formation of prostaglandins
ated with hyper-reninemia. by inhibiting the enzymatic activity of COX-1 and COX-2Conclusion. These studies demonstrate that COX-2 may be
[9]. COX-1 has been proposed to be a housekeepingdetected in the macula densa of humans. Since macula densa
enzyme, and its inhibition is associated with the well-COX-2 was detected in cases of BLS, renal COX-2 expression
may be linked to volume and renin status in humans, as well known side effects of NSAIDs, particularly gastric ulcers
as in animals. and bleeding [9]. COX-2 is usually not expressed in most
tissues but can be induced by growth factors and in-
flammatory cytokines [10]. In contrast to most other
Bartter-like syndrome (BLS) comprises a set of auto- tissues, the kidney constitutively expresses both COX
somal recessively inherited renal tubular disorders charac- isozymes. COX-1 is expressed predominantly within cells
terized by hyperprostaglandinuria, hyper-reninemia, and of the collecting duct [11], while in rodents, COX-2 has
been shown to be expressed in medullary interstitial cells
and in cells in the macula densa [12–14].Key words: renin, prostaglandins, congenital tubular disorders, volume,
urinary PGE2 excretion, salt wasting. The macula densa is a specialized cluster of the cortical
thick ascending limb cells that are thought to sense lumi-Received for publication March 1, 2000
nal salt concentration and thereby control glomerularand in revised form May 17, 2000
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renal artery stenosis [17] induce expression of COX-2 inÓ 2000 by the International Society of Nephrology
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Table 1. Expression of COX-2 mRNA and protein in patients with Horsfall and anti-COX-2 antibodies were diluted 1:200
Bartter-like syndrome
in TBST (50 mmol/L Tris, pH 7.5, 300 mmol/L NaCl, and
Combined 0.05% Tween 20) containing 1% bovine serum albumin
Genetic defect COX-2 ISH COX-2 Histo ISH and Histo (BSA), 5% normal horse serum, and 1% nonfat dry
ClCnKB neg pos pos milk. Immunolabeling was detected using a biotinylated
ClCnKB pos neg pos
rabbit anti-goat antibody followed by visualization with? (HPS/aBS with SND) pos pos pos
NaKCl2 neg pos pos an avidin-biotin horseradish peroxidase labeling kit (Vec-
NaKCl2 pos pos pos tastain ABC kit) and diaminobenzidine staining.
NaKCl2 pos neg pos
RomK pos pos pos
In situ hybridizationRomK ND pos pos
RomK neg pos pos In situ hybridization was performed as previously de-
RomK neg pos pos
scribed [19]. Briefly, prior to hybridization, tissue sec-? pos neg pos
Total 6/10 8/11 11/11 tions were deparaffinized, refixed in paraformaldehyde,
treated with proteinase K (20 mg/mL), washed with PBS,Abbreviations are: COX, cyclooxygenase-2; ISH, in situ hybridization; Histo,
immunohistochemistry; pos, positive; neg, negative; ND, not done. refixed in 4% paraformaldehyde, and treated with trietha-
nolamine plus acetic anhydride (0.25% vol/vol). 35S-labeled
antisense and sense riboprobes synthesized from the
COX-2 specific 39 untranslated region of the human COX-2the macula densa. A stimulatory effect of COX-2–derived
cDNA (471 bp) were hybridized to the section at 558Cproducts on renin release has been suggested by studies
for 18 hours. After hybridization and stringency washes,showing that selective COX-2 inhibitors reduce renin
sections were treated with RNase A (10 mg/mL) at 378Crelease in animals with renal artery stenosis or salt and
for 30 minutes. Slides were dehydrated, air-dried, dippedvolume depletion [17, 18]. In the present studies, we
in photoemulsion (Ilford K5, Knutsford, Cheshire, UK),examined whether COX-2 is also expressed in the renal
and exposed for four to five days at 48C. Photomicro-macula densa of patients with clinically and/or geneti-
graphs were viewed with a Zeiss Axioskop microscopecally defined BLS, a disease associated with activation
using either bright-field or dark-field optics. Picturesof the renin-angiotensin system. In addition, COX-2 ex-
were captured with a digital camera (Spot-Cam; Diag-pression was analyzed in several patients without under-
nostic Instruments, Sterling Heights, MI, USA), andlying BLS.
color composites were generated by using Adobe Pho-
toshop version 4.0 on a Power Macintosh.
METHODS
Patients RESULTS
Renal biopsies were performed in children with genet- In renal tissue deemed unsuitable for transplantation,
ically or clinically defined BLS to evaluate the effects COX-2 immunoreactive-protein (ir) was observed in
of long-term indomethacin treatment. Informed written cells of the macula densa in one of the six cases, that
consent from the parents was obtained. In addition, we being a kidney from a patient with congestive heart fail-
analyzed renal tissue (N 5 6) from kidneys deemed un- ure (Fig. 1A). Only some maculae densae showed COX-2
suitable for kidney transplantation. Medical history did labeling. Typically, COX-2 ir-protein was restricted to 5
not indicate conditions associated with salt or volume to 10 cells. Serial sections processed with anti-Tamm-
depletion in five cases. One patient had congestive heart Horsfall antibodies (Fig. 1B) showed that COX-2 ir-pro-
failure and required an aortic balloon pump for pressure tein expression was restricted to the cells of the macula
support prior to death. Approval by the local ethics com- densa and did not overlap with Tamm-Horsfall immuno-
mittee was obtained. reactive protein. In five cases with no underlying renal
or cardiovascular pathology, COX-2 immunoreactive
Immunostaining protein was not observed in the macula densa but was
Sections were cut at 3 mm thickness, deparaffinized present in interstitial cells in the medulla (data not
in xylene, and incubated for 30 minutes in methanol shown). In patients with BLS COX-2 immunoreactivity
containing 0.3% H2O2 to block endogenous peroxidase was also detected in the macula densa in 8 out of 11
activity. Primary antibodies were obtained from Santa biopsies. The underlying mutations in these patients are
Cruz (goat polyclonal anti-human COX-2: C-20, sc#1745; provided in Table 1. Figure 1C shows expression of COX-2
Santa Cruz, CA, USA). For detection of COX-2, immu- in a patient with a genetic defect in the gene encoding
noreactive protein sections were microwaved for three RomK; Figure 2D demonstrates COX-2 in a patient with
minutes in phosphate-buffered saline (PBS) containing a genetic defect in the gene encoding the furosemide
sensitive NaK2Cl transporter. Typically, COX-2 protein0.1 mol/L sodium citrate, pH 6.0. Polyclonal anti-Tamm-
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Fig. 1. Expression of cyclooxygenase-2 (COX-2) immunoreactive protein. Serial sections of renal cortex from a patient with congestive heart
failure were processed with anti–COX-2 (A ) and anti-Tamm-Horsfall antibodies (B). COX-2 immunoreactive protein is expressed in the cells of
the macula densa but not in the surrounding cells of the thick ascending limb of Henle, which are identified by expression of Tamm-Horsfall
protein (B). Expression of COX-2 immunoreactive protein was also observed in a patient with a genetic defect in the gene encoding RomK (C )
and in a patient with a genetic defect in the furosemide-sensitive NaK2Cl transporter (D). Publication of this figure in color was made possible
by an unrestricted educational grant from Merck Pharmaceuticals, Inc.
expression was not abundant. Hyperplasia of the juxta- that treatment of female volunteers with nimesulide, a
glomerular apparatus was also seen (Fig. 1 C, D, arrows). clinically approved COX-2 inhibitor, suppressed furose-
In 6 out of 10 biopsies, COX-2 mRNA expression was mide-induced renin levels [22]. This supports a relation-
also detected by in situ hybridization (Table 1). In one ship between COX-2 and plasma renin activity in humans.
patient with a mutation in the gene encoding a basolat- COX-2 was also abundantly expressed in the macula
eral chloride channel, COX-2 mRNA was expressed in densa of a patient with congestive heart failure, which
the renal medulla (Fig. 2A) in a nephron segment, possi- is in keeping with the concept that reduced luminal salt
bly the thick ascending limb of Henle (TALH). In a patient delivery or entry of salt into the macula densa cells may
with clinically confirmed BLS, COX-2 mRNA is expressed be the stimulus that drives COX-2 expression.
in the macula densa (Fig. 2B, brightfield; Fig. 2C, dark- Increased renal production of prostaglandin E2 is both
field). Expression of COX-2 protein and mRNA was a characteristic feature and an important indicator of
also observed in a HPS/aBS patient with chronic renal therapeutic efficacy in BLS [1]. Our finding of COX-2
failure and sensorineural deafness (HPS/aBS with SND). in human macula densa and possibly thick ascending
limb of Henle salt suggests that the excessive prostaglan-
din E2 formation in BLS may be at least partly attributedDISCUSSION
to COX-2. This finding provides a rationale for testing
Expression of COX-2 in the macula densa has been COX-2 inhibitors as a therapeutic alternative to nonse-
reported in rats, rabbits, and mice [12–14], and salt deple- lective COX inhibitors such as indomethacin in patients
tion has been shown to induce COX-2 in the macula with BLS, to avoid gastrointestinal toxicity.
densa [14, 18]. In contrast, previous reports did not detect In summary, we have shown that COX-2 is expressed
COX-2 in macula densa of primates or humans [20, 21]. in the macula densa of patients with BLS and in a patient
We now report that COX-2 is also expressed in the with congestive heart failure. This may reflect enhanced
renal macula densa of humans with documented BLS or renal COX-2 expression in these syndromes. By analogy
congestive heart failure, diseases that are characterized with studies in rodents, we speculate that macula densa-
by activation of the renin-angiotensin system. The pau- associated COX-2 expression may be involved in the
city of glomeruli within biopsy tissue and the initial ob-
regulation of renin release in humans. Given the com-
servation [14] that only a minority of rat maculae densae
mon gastrointestinal side-effects observed with the high
display expression of COX-2, even when induced by a
doses of indomethacin required for treatment of BLS,low-salt diet, may explain the finding that not all of the
the findings of this study support investigational thera-renal biopsies analyzed were positive. COX-2 labeling
peutic trials with COX-2 inhibitors in patients with BLS.was not detected in kidneys from control subjects, consis-
tent with earlier studies that also failed to detect COX-2
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Fig. 2. Expression of cyclooxygenase-2 (COX-2) mRNA in patients with Bartter-like syndrome (BLS). COX-2 mRNA is expressed in a nephron
segment in the renal medulla in patient with a defect in the basolateral chloride channel. COX-2 mRNA expression in the macula densa is shown
in a patient with clinically confirmed BLS (B, brightfield; C, darkfield). Publication of this figure in color was made possible by an unrestricted
educational grant from Merck Pharmaceuticals, Inc.
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